AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30831331 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 27718765 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ALA 400 mg daily for 30 days
Number of subjects: 40
Study 27718765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26390908 — intervention group
Group type: EXPERIMENTAL
Intervention: Duette multifocal (SynergEyes)
Number of subjects: 8
Study 26390908 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Optix AQUA multifocal (Alcon)
Number of subjects: 8
Study 26390908 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofinity multifocal (CooperVision)
Number of subjects: 8
Study 23943184 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole prophylaxis
Number of subjects: 599
Study 23943184 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole prophylaxis
Number of subjects: 599
Study 20833455 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated pharmacology and medicines management curriculum
Number of subjects: 120
Study 20833455 — intervention group
Group type: COMPARATOR
Intervention: Usual curriculum (control group)
Number of subjects: 120
Study 19214921 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0
Study 19214921 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Number of subjects: 0
Study 19214921 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 0
Study 16886113 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy (5‐fluorouracil, pirarubicin, mitomycin) for two courses
Number of subjects: 368
Study 16886113 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial infusion chemotherapy (5‐fluorouracil, pirarubicin, mitomycin) for four courses
Number of subjects: 368
Study 15800329 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) 75 mg/m²/d orally concomitantly with RT (60 Gy in 30 fractions) followed by six cycles of TMZ (150 mg/m² on days 1-5 and 15-19 every 28 days)
Number of subjects: 130
Study 15800329 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone (60 Gy in 30 fractions)
Number of subjects: 130
Study 11303488 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron (120 mg Fe as FeSO4) and folic acid (500 microg)
Number of subjects: 366
Study 11303488 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron (120 mg Fe as FeSO4) and folic acid (500 microg) plus vitamin A (4800 RE)
Number of subjects: 366
Study 11303488 — intervention group
Group type: COMPARATOR
Intervention: Daily iron and folic acid (national program)
Number of subjects: 366
Study 11303488 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 366
Study 9470402 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation-induced knee flexion/extension (ES)
Number of subjects: 16
Study 9470402 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary knee flexion/extension (VOL)
Number of subjects: 16
Study 9470402 — intervention group
Group type: COMPARATOR
Intervention: Passive knee flexion/extension (PAS)
Number of subjects: 16
Study 8336988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued for mood experience
Number of subjects: 49
Study 8336988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued for pain experience
Number of subjects: 49
Study 8336988 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of chosen words
Number of subjects: 49
Study 8336988 — intervention group
Group type: COMPARATOR
Intervention: General anaesthetic
Number of subjects: 49
Study 3720176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nifedipine (4.5 mg in 45 minutes)
Number of subjects: 0
Study 3720176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (20 mg)
Number of subjects: 0
Study 3720176 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (not specified dosage)
Number of subjects: 0
Study 2742440 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual physician advice + 2 counseling sessions with a smoking cessation counselor
Number of subjects: 155
Study 2742440 — intervention group
Group type: COMPARATOR
Intervention: Usual physician advice
Number of subjects: 155
Study 2742440 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher motivation smokers in intervention group
Number of subjects: 155
Study 2742440 — intervention group
Group type: COMPARATOR
Intervention: Higher motivation smokers in control group
Number of subjects: 155
Study 30970152 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted behavioural based intervention (asynchronous e-learning module)
Number of subjects: 420
Study 30970152 — intervention group
Group type: COMPARATOR
Intervention: Knowledge based active control (asynchronous e-learning module)
Number of subjects: 420
Study 30970152 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (regardless of study arm)
Number of subjects: 420
Study 28631582 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 500 mg/d for 8 weeks
Number of subjects: 8
Study 28631582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 28631582 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE)
Number of subjects: 8
Study 26156280 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O-O2 sedation
Number of subjects: 40
Study 26156280 — intervention group
Group type: COMPARATOR
Intervention: O2 (control)
Number of subjects: 40
Study 23515614 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF)
Number of subjects: 232
Study 23515614 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cyclin D1 expression
Number of subjects: 232
Study 23515614 — intervention group
Group type: COMPARATOR
Intervention: High cyclin D1 expression
Number of subjects: 232
Study 21740089 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared-LED (850 nm) plus treadmill training (45 minutes twice a week for 3 months at 85%-90% HR(max), 39 mW/cm(2), fluence of 106 J/cm(2))
Number of subjects: 20
Study 21740089 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training only (control group)
Number of subjects: 20
Study 19908337 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-sorbitol (F-S) ingestion (25 g fructose/5 g sorbitol)
Number of subjects: 26
Study 19908337 — intervention group
Group type: COMPARATOR
Intervention: Glucose ingestion (50 g glucose)
Number of subjects: 26
Study 19908337 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-sorbitol (F-S) ingestion
Number of subjects: 26
Study 16289976 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 30
Study 16289976 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 30
Study 15160331 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose adjuvant chemotherapy
Number of subjects: 18
Study 10978398 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux biocompatible membrane
Number of subjects: 84
Study 10978398 — intervention group
Group type: COMPARATOR
Intervention: Conventional cellulose membrane
Number of subjects: 84
Study 10978398 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin therapy in conventional group
Number of subjects: 84
Study 10978398 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy in experimental group
Number of subjects: 84
Study 10978398 — intervention group
Group type: COMPARATOR
Intervention: Dialysis dose (Kt/V) in conventional group
Number of subjects: 84
Study 10978398 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis dose (Kt/V) in experimental group
Number of subjects: 84
Study 10978398 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta(2)-microglobulin levels in experimental group
Number of subjects: 84
Study 10978398 — intervention group
Group type: COMPARATOR
Intervention: Beta(2)-microglobulin levels in conventional group
Number of subjects: 84
Study 10978398 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin doses in conventional group
Number of subjects: 84
Study 10978398 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin doses in experimental group
Number of subjects: 84
Study 10978398 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin plasma levels in conventional group
Number of subjects: 84
Study 10978398 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin plasma levels in experimental group
Number of subjects: 84
Study 9565733 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmenting agent with SSRI antidepressant
Number of subjects: 80
Study 9565733 — intervention group
Group type: COMPARATOR
Intervention: SSRI antidepressant
Number of subjects: 80
Study 9565733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8417716 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (digitalization)
Number of subjects: 80
Study 8417716 — intervention group
Group type: COMPARATOR
Intervention: No digoxin (not digitalized)
Number of subjects: 80
Study 8417716 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (malignant disease)
Number of subjects: 80
Study 8417716 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (benign disease)
Number of subjects: 80
Study 3746171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropping one tar group
Number of subjects: 3
Study 3746171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropping two tar groups
Number of subjects: 3
Study 3746171 — intervention group
Group type: COMPARATOR
Intervention: All groups of smokers
Number of subjects: 3
Study 31483910 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol treatment (800 mg/d for 40 days)
Number of subjects: 40
Study 31483910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29724305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine continuous pumping group
Number of subjects: 60
Study 29724305 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 28464754 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach (PA)
Number of subjects: 80
Study 28464754 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach (LA)
Number of subjects: 80
Study 26290682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin 10/20 mg
Number of subjects: 74
Study 26290682 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 74
Study 26290682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 23396737 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics treatment (Lepicol formula containing Lactobacillus plantarum, Lactobacillus deslbrueckii, Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum) for 6 months
Number of subjects: 20
Study 23396737 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 6 months
Number of subjects: 20
Study 20512995 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol phenylbutyrate (GPB)
Number of subjects: 48
Study 20512995 — intervention group
Group type: COMPARATOR
Intervention: Sodium phenylbutyrate (NaPBA)
Number of subjects: 48
Study 18400716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkles (SP)
Number of subjects: 413
Study 18400716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritabs (NT)
Number of subjects: 413
Study 18400716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutributter (NB)
Number of subjects: 413
Study 18400716 — intervention group
Group type: COMPARATOR
Intervention: No Intervention (NI)
Number of subjects: 413
Study 18400716 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention groups (SP, NT, NB)
Number of subjects: 413
Study 16967147 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-salicylic acid (aspirin)
Number of subjects: 81
Study 16967147 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins (retinol, pyridoxine chlorhydrate, tocopherol acetate)
Number of subjects: 81
Study 16967147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 14575293 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 104
Study 14575293 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 104
Study 14575293 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of patients with sepsis and septic shock
Number of subjects: 104
Study 10409200 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP, 2 micrograms . kg(‐1). min(‐1))
Number of subjects: 16
Study 10409200 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) + phenylephrine (PE, 0.9 +/‐ 0.15 micrograms . kg(‐1). min(‐1))
Number of subjects: 16
Study 10409200 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose
Number of subjects: 16
Study 7573265 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intervention of four to six visits dealing with psychosocial support and education about health-related habits
Number of subjects: 2235
Study 7573265 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 2235
Study 2075082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1,500 mg plus metronidazole 500 mg (3 doses)
Number of subjects: 165
Study 2075082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 2075082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg (single dose)
Number of subjects: 165
Study 6163343 — intervention group
Group type: EXPERIMENTAL
Intervention: RIA‐PAP test
Number of subjects: 211
Study 6163343 — intervention group
Group type: COMPARATOR
Intervention: Conventional enzymatic PAP study
Number of subjects: 211
Study 6163343 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RIA and enzyme studies
Number of subjects: 211
Study 6163343 — intervention group
Group type: COMPARATOR
Intervention: Control men
Number of subjects: 211
Study 6163343 — intervention group
Group type: COMPARATOR
Intervention: Control men (age-related)
Number of subjects: 211
Study 29469046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) with AMO therapy
Number of subjects: 12
Study 26655485 — intervention group
Group type: EXPERIMENTAL
Intervention: SPEED questionnaire
Number of subjects: 657
Study 26655485 — intervention group
Group type: EXPERIMENTAL
Intervention: OSDI questionnaire
Number of subjects: 657
Study 26655485 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between OSDI and SPEED
Number of subjects: 657
Study 26655485 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis of SPEED
Number of subjects: 657
Study 26655485 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis of SPEED
Number of subjects: 657
Study 25132283 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) using high‐viscosity glass‐ionomer (HVGIC) Ketac Molar Easymix
Number of subjects: 280
Study 25132283 — intervention group
Group type: COMPARATOR
Intervention: Conventional restorative treatment with amalgam (CRT)
Number of subjects: 280
Study 22642688 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-voiced agent with human-like gestures, facial expression, eye gaze, and body movement
Number of subjects: 0
Study 22642688 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-voiced agent
Number of subjects: 0
Study 22642688 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly embodied agent
Number of subjects: 0
Study 22642688 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent agent characteristics
Number of subjects: 0
Study 20124127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary eptifibatide administration
Number of subjects: 0
Study 20124127 — intervention group
Group type: COMPARATOR
Intervention: Intravenous eptifibatide administration
Number of subjects: 0
Study 17880431 — intervention group
Group type: EXPERIMENTAL
Intervention: Two additional photographs illustrating the two key steps of the procedure
Number of subjects: 28
Study 17880431 — intervention group
Group type: COMPARATOR
Intervention: No further explanation of the reconstitution device
Number of subjects: 28
Study 16197659 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate plus colesevelam HCl
Number of subjects: 129
Study 16197659 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate monotherapy
Number of subjects: 129
Study 11998963 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal therapy (17beta‐estradiol 0.05 mg/d + norethisterone acetate 0.25 mg/d)
Number of subjects: 96
Study 11998963 — intervention group
Group type: COMPARATOR
Intervention: Oral therapy (conjugated equine estrogens 0.625 mg/d + medroxyprogesterone acetate 10 mg/d)
Number of subjects: 96
Study 9637637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-controlled ventilation group (200 microg fentanyl: two doses of 50 microg and one dose of 100 microg, spaced 6 min)
Number of subjects: 22
Study 9637637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-spontaneous ventilation group (200 microg fentanyl)
Number of subjects: 22
Study 9637637 — intervention group
Group type: COMPARATOR
Intervention: Propofol group (propofol alone)
Number of subjects: 22
Study 8089541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansentron alone (Group A)
Number of subjects: 80
Study 8089541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansentron plus methylprednisolone (Group B)
Number of subjects: 80
Study 2678520 — intervention group
Group type: EXPERIMENTAL
Intervention: Triampur (TP) - 2 tablets containing 12.5 mg HCT and 25 mg T each
Number of subjects: 57
Study 2678520 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) - 25 mg
Number of subjects: 57
Study 2678520 — intervention group
Group type: EXPERIMENTAL
Intervention: Triampur (TP) - doubled doses
Number of subjects: 57
Study 2678520 — intervention group
Group type: EXPERIMENTAL
Intervention: Triampur (TP)
Number of subjects: 57
Study 811075 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine alone
Number of subjects: 117
Study 811075 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine in combination with phenobarbital and diphenylhydantoin
Number of subjects: 117
Study 811075 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 117
Study 31160244 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behaviour Therapy (iCBT) for Fear of Birth
Number of subjects: 19
Study 31160244 — intervention group
Group type: COMPARATOR
Intervention: Midwifery led counselling (standard care)
Number of subjects: 19
Study 30394805 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon(R) for 1 month
Number of subjects: 450
Study 30394805 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon(R) for 3 months
Number of subjects: 450
Study 30394805 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 450
Study 28427806 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 52
Study 28427806 — intervention group
Group type: COMPARATOR
Intervention: Ghrelin, IL-6, TNF-α
Number of subjects: 52
Study 25919978 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain interference during treatment in UKATT
Number of subjects: 2125
Study 25919978 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain interference during treatment in COMBINE
Number of subjects: 2125
Study 25919978 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain interference following treatment in COMBINE
Number of subjects: 2125
Study 25919978 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain interference during treatment in UKATT (after controlling for other factors)
Number of subjects: 2125
Study 25919978 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain interference following treatment in COMBINE (after controlling for other factors)
Number of subjects: 2125
Study 24598948 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg/day)
Number of subjects: 68
Study 24598948 — intervention group
Group type: COMPARATOR
Intervention: Control (no beta-blockers)
Number of subjects: 68
Study 21609527 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical hypertrophic cardiomyopathy (AHCM)
Number of subjects: 160
Study 21609527 — intervention group
Group type: COMPARATOR
Intervention: Typical hypertrophic cardiomyopathy (OHCM)
Number of subjects: 160
Study 21609527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging
Number of subjects: 160
Study 19170990 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support condition (donate with a supportive research assistant)
Number of subjects: 65
Study 19170990 — intervention group
Group type: COMPARATOR
Intervention: Standard donation controls (donate as usual)
Number of subjects: 65
Study 16424650 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ferrous iron supplement (as fumarate)
Number of subjects: 404
Study 16424650 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ferrous iron supplement (as fumarate)
Number of subjects: 404
Study 16424650 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg ferrous iron supplement (as fumarate)
Number of subjects: 404
Study 16424650 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ferrous iron supplement (as fumarate)
Number of subjects: 404
Study 15231459 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable plain gut sutures (group A)
Number of subjects: 95
Study 15231459 — intervention group
Group type: COMPARATOR
Intervention: Nonabsorbable nylon sutures (group NA)
Number of subjects: 95
Study 11167166 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm with on-site hemostasis monitoring (group A)
Number of subjects: 58
Study 11167166 — intervention group
Group type: COMPARATOR
Intervention: Clinician's judgement (group B)
Number of subjects: 58
Study 11167166 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 9247455 — intervention group
Group type: EXPERIMENTAL
Intervention: Small bowel enteroclysis (SBE)
Number of subjects: 26
Study 9247455 — intervention group
Group type: COMPARATOR
Intervention: Small bowel follow-through (SBFT)
Number of subjects: 26
Study 7664435 — intervention group
Group type: EXPERIMENTAL
Intervention: d-sotalol 200 mg BID
Number of subjects: 233
Study 7664435 — intervention group
Group type: EXPERIMENTAL
Intervention: d-sotalol 50 mg BID
Number of subjects: 233